Features of intestinal microbiota in chronic pyelonephritis in a patient with Mayer–Rokitansky–Kustner–Hauser syndrome

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Mayer–Rokitansky–Küstner–Hauser syndrome is a congenital anomaly in the development of the female reproductive system, the essence of which is a violation of the intrauterine development of the Müllerian ducts, causing complete aplasia of the vagina and uterus. Deviation is a total or partial absence uterus, two upper thirds of the vagina, most often in combination with various anomalies of organs and systems, such as excretory, cardiovascular. Currently, the causes of this pathology are not fully understood studied. According to the World Health Organization, the percentage of hereditary factors intrauterine development disorders is approximately 10 to 25%. It is known that patients with this pathology often suffer from diseases of the urinary system (pyelonephritis). Chronic pyelonephritis is a common pathology in any age group due to excessive growth of the bacterial flora. The main causative agent, most often, are representatives of the intestinal microbiota (Escherichia coli, Enterococcus, Staphylococcus). Determination of the genus and species composition of the intestinal microbiota can serve as one of the diagnostic signs that contribute to the timely correction of the main therapy. Presented clinical case demonstrates a change in the biodiversity of the intestinal microbiota in a patient with Mayer–Rokitansky–Küstner–Hauser syndrome, which entails timely correction of drug therapy regimens in relation to chronic pyelonephritis and achieving remission. Thus, the study of changes in the composition of the intestinal microflora can become a new criterion in the diagnosis and treatment of this disease at an early stage.

全文:

受限制的访问

作者简介

Svetlana Lagutina

N.N. Burdenko Voronezh State Medical University

编辑信件的主要联系方式.
Email: svlagutina97@mail.ru

Resident Doctor, Department of Polyclinic Therapy

俄罗斯联邦, Voronezh

Olga Skuratova

N.N. Burdenko Voronezh State Medical University

Email: prokopova15@mail.ru

Resident Doctor, Department of Polyclinic Therapy

俄罗斯联邦, Voronezh

Pavel Chizhkov

N.N. Burdenko Voronezh State Medical University

Email: qooleer@yandex.ru

Resident Doctor, Department of Polyclinic Therapy

俄罗斯联邦, Voronezh

Anna Zuykova

N.N. Burdenko Voronezh State Medical University

Email: zuikova@vrngmu.ru

MD, PhD, Dr. Med. Sci., Professor, Head, Department of Polyclinic Therapy

俄罗斯联邦, Voronezh

Anastasia Kurguzova

N.N. Burdenko Voronezh State Medical University

Email: kuguzova@vrngmu.ru

Assistant Professor, Department of Polyclinic Therapy

俄罗斯联邦, Voronezh

Elena Esina

N.N. Burdenko Voronezh State Medical University

Email: esina@vrngmu.ru

MD, PhD, Dr. Med. Sci., Professor, Department of Polyclinic Therapy

俄罗斯联邦, Voronezh

Irina Dobrynina

N.N. Burdenko Voronezh State Medical University

Email: dobrynina@yandex.ru

MD, PhD, Associate Professor, Department of Polyclinic

俄罗斯联邦, Voronezh

Daria Martynenko

N.N. Burdenko Voronezh State Medical University

Email: dsmart@yandex.ru

6th year student of the Faculty of Medicine, Department of Polyclinic Therapy

俄罗斯联邦, Voronezh

Kirill Samkov

N.N. Burdenko Voronezh State Medical University

Email: kdsamkov@yandex.ru

6th year student of the Faculty of Medicine, Department of Polyclinic Therapy

俄罗斯联邦, Voronezh

参考

  1. Smol’nova TYu, Bobkova MV, Asaturova AV, et al. Are there phenotypic manifestations of connective tissue dysplasia syndrome in patients of reproductive age with aplasia of the vagina and uterus? Russian Bulletin of Obstetrician-Gynecologist. 2021;21(2):7381. (In Russ.) doi: 10.17116/rosakush20212102173
  2. Berg G, Rybakova D, Fischer D, et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome. 2020;8:103. doi: 10.1186/s40168-020-00875-0
  3. Dry J, Bessede T, Patard JJ. Management of acute pyelonephritis. Progrès en Urologie. 2022;22(14): 871–875. (In French) doi: 10.1016/j.purol.2012.06.002
  4. Hillman ET, Lu H, Yao T, Nakatsu CH. Microbial ecology along the gastrointestinal tract. Microbes Environ. 2017;32(4):300–313. doi: 10.1264/jsme2.ME17017
  5. Lagrine M, Bennaoui F, El Idrissi Slitine N, Rabou Maoulainine F. Epidemiology of urinary tract infection in neonatal intensive care unit of Mohammed VI University Hospital in Marrakech. Open Infect Dis J. 2018;10: 156–159. doi: 10.2174/1874279301810010156
  6. Meštrović T, Matijašić M, Perić M, et al. The role of the gut, vagina, and urinary tract microbiome in urinary tract infections: from bench to bedside. Diagnostics (Basel). 2021;11(1):7. doi: 10.3390/diagnostics11010007
  7. Nishioka H, Doi A, Takegawa H. Pyelonephritis in Japan caused by Salmonella enterica subsp. Arizonae. J Infect Chemother. 2017;23(12):841–843. doi: 10.1016/j.jiac.2017.08.001
  8. Praetorius H. Bacteria and the host: a history of purinergic signaling in urinary tract infections. Am J Physiol Cell Physiol. 2021;321(1): C134–C146. doi: 10.1152/ajpcell.00054.2021
  9. Rinninella E, Raul P, Chintoni M, Franceschi F, et al. What is the composition of a healthy gut microbiota? A changing ecosystem with age, rare occurrences, nutrition and infections. Microorganisms. 2019;7(1):14. doi: 10.3390/microhorogisms7010014
  10. Stecher B. Roles of inflammation, nutrient availability, and commensal microbiota in intestinal pathogenic infection. Microbiol Spectr. 2015;3:3. doi: 10.1128/microbiolspec.MBP-0008-2014
  11. Stepanova N. How advanced is our understanding of the role of intestinal barrier dysfunction in the pathogenesis of recurrent urinary tract infections. Front Pharmacol. 2022;13:780122. doi: 10.3389/fphar.2022.780122
  12. Sturov NV, Popov SV, Zhukov VA, et al. Intestinal microbiota correction in the treatment and prevention of urinary tract infection. Urol Res Pract. 2022;48(6): 406–414. doi: 10.5152/tud.2022.22119
  13. Warby K.J., Olson B.S., Dodson K.W., et al. Establishing the role of the gut microbiota in susceptibility to recurrent urinary tract infections // J Clin Invest. 2022. Vol. 132, No. 5. ID e158497. doi: 10.1172/JCI158497
  14. www.rlsnet.ru [Internet]. Ehnterol. Available at: https://www.rlsnet.ru/drugs/enterol-3539 (In Russ.)

补充文件

附件文件
动作
1. JATS XML

版权所有 © Eco-Vector, 2023



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 69634 от 15.03.2021 г.